Home » Drug Information » FDA Approved Drugs » 1999
Medical Areas: Endocrinology | Oncology | Otolaryngology (Ear, Nose, Throat)
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: U.S. Bioscience, Alza
Approval Status: Approved June 1999
Treatment Area: Oncology
Ethyol has been approved to reduce xerostomia in patients
undergoing post-operative radiation treatment for head and neck
cancer, where the radiation port includes a substantial portion of
the parotid glands. Xerostomia--a chronic dry mouth condition--is a
severe and often irreversible side effect of radiation therapy
caused by damage to the salivary glands.
Side effects of Ethyol plus radiation in a Phase III study
included nausea and vomiting which were sometimes severe. Side
effects also included hypotension, fever, allergic-type skin
reactions, dizziness/lightheadedness, fatigue/lethargy,
rigors/chills, sneezing, sleepiness/somnolence, and flushing.